tbuckley/cabot-search huggingface dataset:
Evaluation of bone pain in carcinoma of the lung. Role of the localized false-negative scan
Authors: H. D. Covelli
Journal: JAMA (1980)

False-negative bone scans localized to the vertebral column were detected in ten patients with primary carcinoma of the lung. All patients had macroscopic vertebral metastases at autopsy despite recent normal technetium Tc 99m bone scans and skeletal roentgenograms. Bone scans were 96% accurate in detecting nonvertebral metastases that were grossly visible at postmortem, with seven patients demonstrating multiple skeletal defects. False-negative studies of the vertebral column apparently prevented both the clinician and radiotherapist from treating symptomatic metastases in eight patients despite the administration of radiotherapy to other scan-positive symptomatic areas or to the primary tumor site. (<i>JAMA</i>1980;244:2625-2627)
Abstract 4308: Phosphatidic acid binds to ERK3 and stimulates phosphorylation of the ERK3 activation loop
Authors: Amanda Myers, Hitham Aldharee, Shimpi Bedi, Weiwen Long
Journal: Cancer Research (2019)

Abstract Protein kinases modulate the activity of other proteins through phosphorylation and themselves are often regulated by phosphorylation of their activation loop. Extracellular signal-Regulated Kinase 3 (ERK3) is an atypical member of the ERK family of Mitogen-Activated Protein Kinases (MAPK), with a SerGlu-Gly (SEG) motif in its activation loop rather than the canonical Thr-Xaa-Tyr (TXY) motif of ERK1/2. Activation loop phosphorylation of ERK3 is not regulated by the signals known to activate ERK1/2, such as mitogenic growth factors. The cellular stimuli activating ERK3 kinase are virtually unknown. Some kinases, including mTOR and p21 activated kinase 1 and 2 (PAK1/2), are stimulated by binding to certain phospho-lipid signaling molecules, such as phosphatidic acids. Here, we show ERK3 binds to specific phospholipids in vitro, and the C-terminal domain may be important for this interaction. In addition, ERK3 can localize to the cell membrane. Further, phosphatidic acid stimulated phosphorylation of the activation loop in ERK3. Together, these results suggest that ERK3 kinase activity might be upregulated by specific phosphatidic acid species in cells. Citation Format: Amanda Myers, Hitham Aldharee, Shimpi Bedi, Weiwen Long. Phosphatidic acid binds to ERK3 and stimulates phosphorylation of the ERK3 activation loop [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4308.
Regression analysis of time trends in perinatal mortality in Germany 1980-1993.
Authors: H Scherb, E Weigelt, I Brüske-Hohlfeld
Journal: Environmental Health Perspectives (2000)

Numerous investigations have been carried out on the possible impact of the Chernobyl accident on the prevalence of anomalies at birth and on perinatal mortality. In many cases the studies were aimed at the detection of differences of pregnancy outcome measurements between regions or time periods. Most authors conclude that there is no evidence of a detrimental physical effect on congenital anomalies or other outcomes of pregnancy following the accident. In this paper, we report on statistical analyses of time trends of perinatal mortality in Germany. Our main intention is to investigate whether perinatal mortality, as reflected in official records, was increased in 1987 as a possible effect of the Chernobyl accident. We show that, in Germany as a whole, there was a significantly elevated perinatal mortality proportion in 1987 as compared to the trend function. The increase is 4.8% (p = 0.0046) of the expected perinatal death proportion for 1987. Even more pronounced levels of 8.2% (p = 0. 0458) and 8.5% (p = 0.0702) may be found in the higher contaminated areas of the former German Democratic Republic (GDR), including West Berlin, and of Bavaria, respectively. To investigate the impact of statistical models on results, we applied three standard regression techniques. The observed significant increase in 1987 is independent of the statistical model used. Stillbirth proportions show essentially the same behavior as perinatal death proportions, but the results for all of Germany are nonsignificant due to the smaller numbers involved. Analysis of the association of stillbirth proportions with the (137)Cs deposition on a district level in Bavaria discloses a significant relationship. Our results are in contrast to those of many analyses of the health consequences of the Chernobyl accident and contradict the present radiobiologic knowledge. As we are dealing with highly aggregated data, other causes or artifacts may explain the observed effects. Hence, the findings should be interpreted with caution, and further independent evidence should be sought.
New Federal stances on TB control may be confusing to health care facilities
Authors: R. Voelker
Journal: JAMA (1993)

THE NEXT generation of federal guidelines and regulations for controlling the spread of tuberculosis (TB) is on its way. But instead of offering much-needed guidance based on consensus among national experts, the new documents may continue to confuse the issue with potentially conflicting advice based on gaps in scientific data on the transmission of<i>Mycobacterium tuberculosis</i>. Earlier this month, the Centers for Disease Control and Prevention (CDC), Atlanta, Ga, published a draft of long-awaited revisions to its 1990 guidelines on the prevention of TB transmission in health care settings. At the same time, the Occupational Safety and Health Administration (OSHA) has drafted a memorandum clarifying how inspections of health care facilities for occupational TB exposure should be carried out. <h3>Potential for Confusion</h3> Several groups, including the American Medical Association (AMA), were invited to review drafts offered by both federal agencies. In a letter to David Zeigler, the acting assistant secretary
CAPE TOWN
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tratado de diagnóstico quirúrgico
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health care reforms still needed in the nation's prisons
Authors: P. Gunby
Journal: JAMA (1981)

It is bad enough to go to jail, especially to one of the county or local facilities said to have deplorable health care and other conditions. It is worse if you have pressing physical or psychological problems that helped put you there but remain unnoticed or ignored behind the cell door. Indeed, these so-called screening failures frequently are behind news reports of prisoner deaths from unrecognized illness or injury, inmate suicide, or violent actions by disturbed detainees, say Jay K. Harness, MD, and Lawrence J. Guzzardi, MD, who are advisers (along with Jonas Rappeport, MD, of Baltimore) to the American Medical Association's correctional facilities health care improvement program. These also are among the reasons why jail receiving officers need training in health assessment—and why a nationwide effort to achieve this cannot come too soon. At the recent Fourth National Conference on Medical Care and Health Services in Correctional Institutions sponsored
Acting up
Authors: Sabreena Malik
Journal: BMJ (2006)

<b>Heather Batten</b> is a drama student at the Poor School in London. In the November 2005 obstetrics and gynaecology objective structured clinical examinations (OSCEs) she played the part of a 30 year old women with an abnormal smear and a pregnant 25 year old whose membranes had ruptured at 22 weeks, as Sabreena Malik found out.
Reply
Authors: Koji Miyanishi, Masayoshi Kobune, Junji Kato
Journal: Hepatology (2015)

Potential conflict of interest: Nothing to report. The study reported by Ruivard et al.1 differed markedly from our own,2 the major difference being the study subjects. Patients with dysmetabolic iron overload (DIOS) were enrolled in their study, rather than individuals with nonalcoholic steatohepatitis (NASH). The patients with DIOS were selected on the basis of serum ferritin levels >400 μg/L, hepatic iron concentration assessed by magnetic resonance imaging >50 μmol/g, and body mass index >27 kg/m2. Accordingly, advanced iron overload is required for a diagnosis of DIOS. In contrast, in our study, only four of the patients with NASH meet these criteria. The remainder of the patients with NASH in our study do not meet their criteria of DIOS. In general, mild or moderate degrees of hepatic iron accumulation are common in patients with NASH. Because we did not observe increased duodenal absorption in our four patients with NASH and DIOS, we agree that iron absorption was lower in patients with DIOS than in lean and overweight controls without iron overload. Overall, we suggest that patients with DIOS exhibit a different pattern of iron absorption from those with NASH.
Artifactual hypoglycemia associated with polycythemia vera
Authors: C. J. Billington
Journal: JAMA (1983)

Artifactual hypoglycemia in patients with leukemia is well recognized. We report herein that patients with polycythemia vera and erythrocytosis demonstrate a similar spurious hypoglycemia caused by accelerated in vitro metabolism of glucose. (<i>JAMA</i>1983;249:774-775)
High-dose nicotine patch therapy. Percentage of replacement and smoking cessation
Authors: L. C. Dale
Journal: JAMA (1995)

<h3>Objective.</h3> —To assess the level of nicotine replacement, evidence of nicotine toxicity, and withdrawal symptom relief with placebo and 11-, 22-, and 44-mg/d doses of transdermal nicotine. A secondary objective was to assess short- and long-term smoking cessation rates. <h3>Design.</h3> —Randomized, double-blind, placebo-controlled inpatient/outpatient trial. <h3>Subjects.</h3> —Seventy-one cigarette smokers stratified according to light (n=23), moderate (n=24), and heavy (n=24) smoking rates. <h3>Interventions.</h3> —After baseline measures were obtained, subjects were randomly assigned to placebo or an 11-, 22-, or 44-mg/d dose of transdermal nicotine and admitted to a special hospital unit for intensive inpatient treatment of nicotine dependence. During the 6-day inpatient stay, daily nicotine and cotinine levels were determined from trough and peak blood samples. Outpatient patch therapy continued for 7 weeks following the hospital stay, and those initially assigned to placebo were randomly assigned to 11 or 22 mg/d. At week 4, the dosage of those initially assigned to 44 mg/d was reduced to 22 mg/d. <h3>Main Outcome Measures.</h3> —Percentage of replacement of cotinine was calculated by dividing the steady-state levels attained during patch therapy by the corresponding baseline levels. Abstinence from smoking was verified by expired air carbon monoxide. Withdrawal symptoms and nicotine toxicity were assessed daily through questionnaires during the inpatient stay. Follow-up visits were at 3,6,9, and 12 months. <h3>Results.</h3> —There was a statistically significant relationship between baseline smoking rate and baseline trough and peak blood cotinine levels (<i>r</i><sub>s</sub>=0.39,<i>r</i><sub>s</sub>=0.45;<i>P</i>&lt;.001 in both instances). A dose-response relationship was observed with higher patch doses, which produced a higher percentage of cotinine replacement and better withdrawal symptom relief. Only one subject (a light smoker assigned to the 44-mg dose) developed signs of nicotine toxicity. There was a positive association between the week 2 patch dose and the biochemically confirmed abstinence at the end of patch therapy (<i>P</i>=.007) but not for subsequent follow-up times. A higher percentage of cotinine replacement was associated with the higher 8-week smoking abstinence rate (<i>P</i>=.03), an association not found at long-term follow-up. <h3>Conclusion.</h3> —A 44-mg/d dose of nicotine patch therapy appears to be safe for use in heavy smokers. Cigarette smoking rates can be used to estimate the initial nicotine patch dose. Monitoring blood cotinine levels at baseline and steady state can be used for assessing the adequacy of nicotine replacement. Withdrawal symptom relief can be improved with more complete nicotine replacement. Achieving a greater percentage of nicotine replacement may increase the efficacy of nicotine patch therapy. (<i>JAMA</i>. 1995;274:1353-1358)
THE BRITISH MEDICAL BENEVOLENT FUND
Journal: BMJ (1905)

iORRESPONDENOE.E X, igo5 either externAinated or enslaved, in which latter position a good many authorities would like to see their medical officialiP.The Monmouth Division, according to the SUPPLMMBHNT of September gth, page 197, has also taken action in the above matter as realizing the very serious principle at issus for the profession.
OS03.5 Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors
Authors: E. Pentsova, X. Lin
Journal: Neuro-Oncology (2017)

Purpose: Establishing the diagnosis of leptomeningeal metastasis (LM) remains challenging due to low sensitivity of CSF cytology and often equivocal MRI findings. In a previous pilot study, we showed that rare cell capture technology (RCCT) could be used to detect circulating tumor cells (CTC) in the cerebrospinal fluid (CSF) of patients with LM from epithelial tumors. To establish the diagnostic accuracy of CSF-CTC in the diagnosis of LM, we applied this technique in a distinct, larger cohort of patients. Methods: In this IRB-approved prospective study, patients with epithelial tumors and clinical suspicion of LM underwent CSF-CTC evaluation and standard MRI and CSF cytology examination. CSF-CTC enumeration was performed through FDA-approved EpCAM-based RCCT immunomagnetic platform. LM was defined by either positive CSF cytology or unequivocal MRI findings. ROC analysis was utilized to define an optimal cut-off for CSF-CTC enumeration. Results: Ninety-five patients were enrolled (36 breast, 31 lung, 28 others); 30 (32%) were diagnosed with LM based on CSF cytology (n = 12), MRI findings (n = 2) or both (n = 16). CSF-CTCs were detected in 43/95 samples (median 19.3 CSF-CTC/ml, range 0.3 to 66.7). Based on ROC analysis, 1 CSF-CTC/ml provided the best threshold to diagnose LM, achieving a sensitivity of 93%, specificity 95%, positive predictive value 90% and negative predictive value 97%. Conclusions: CSF-CTC enumeration through RCCT is a robust tool to diagnose LM, and should be considered in the routine LM workup in solid tumor patients. This research was supported by grants from the Memorial Sloan Kettering Brain Tumor Center. Janssen Diagnostics provided reagents for the analysis but no financial support.
Early intervention aids vision-impaired infants
Authors: H. Cole
Journal: JAMA (1985)

High-concentration oxygen therapy for premature neonates may be lifesaving, but also may predispose the infant to the development of retrolental fibroplasia a Washington, D.C., seminar was told. From a low incidence of 300 reported cases per year in the late 1950s (when the association of the disease with high-dose oxygen first was recognized and lower oxygen concentrations were advocated), this disease has become a significant morbid consequence of aggressive neonatal intensive care (infants especially at risk are those weighing less than 1,000 gm at birth) with more than 4,000 cases per year being reported. These data are according to Robert Machemer, MD, professor and chair, Department of Ophthalmology, Duke University School of Medicine, Durham, NC. Although potentially a cause of total blindness, many cases of retrolental fibroplasia do regress, leaving the patient with some visual acuity. For those children with significant retinal detachment occurring under the force of the contracting
As Influenza Season Progresses, Experts Look Ahead to 1990 Season
Authors: Charles Marwick
Journal: JAMA (1989)

EVEN AS the number of reported cases of influenza is rising rapidly in the United States, the first steps toward combating next year's outbreaks were being taken by an advisory group to the Food and Drug Administration. After reviewing influenza viruses currently in circulation throughout the world—data provided by experts from the Centers for Disease Control, Atlanta, Ga—the group, chaired by Floyd Denny, MD, University of North Carolina, Chapel Hill, recommended: Keeping the present H1N1 type A virus (isolated in 1986 in Taiwan) in next year's vaccine. Consideration of substituting a slightly different representative of H3N2(known as Shanghai/11/87, isolated during the 1987 and 1988 influenza season) for Sichuan/2/87, the antigen in the present vaccine. Giving serious thought to replacing the present B strain with a new type B strain isolated last year in Japan. The final decision on which variants of the H3N2 and B strains to put into the
Journal of Nuclear Medicine, Chicago
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Power Rise Chair
Journal: Annals of the Rheumatic Diseases (1970)

confirm it in 5 years' time.Is this correct ?Have you any plans for extending this investigation?DR.WOOD Not at the moment.Our initial object has been to find quick answers to guide future work, but wehave not yet finished digesting even these preliminary analyses.DR. HILL (Stoke Mandeville) The old criteria of definite and probable comes out if you take out the serology as we did in our follow-up studies of sheep cell tests.DR.WOOD We are hoping to validate this by further analysis of our data.PROF.BYWATERS (Taplow) I would support strongly the thesis that the follow-up is the ultimate validation of any particular theory.
Human Rabies—Montana and Washington, 1997
Journal: JAMA (1997)

On January 5 and January 18, 1997, respectively, a man in Montana and a man in Washington died of neurologic illnesses initially suspected to be Creutzfeldt-Jakob disease (CJD) but diagnosed as rabies encephalitis during subsequent histologic examination on autopsy. The cases were not linked epidemiologically, and no secondary cases occurred. Postexposure prophylaxis (PEP) was administered to 113 potential contacts. This report summarizes the clinical presentations of the cases and the epidemiologic investigations by the Montana Department of Public Health and Human Services and the Washington State Department of Health; nucleic acid sequencing indicated that the silver-haired bat (Lasionycteris noctivagans) and the big brown bat (Eptesicus fuscus), respectively, were the probable sources of exposure.
Bronchoesophageal fistula secondary to Hodgkin's disease
Authors: L. L. Gonzalez
Journal: JAMA (1966)

THE DEVELOPMENT of a bronchoesophageal fistula is a life-threatening complication to which patients readily succumb because of continuous pulmonary aspiration of food and saliva.<sup>1</sup>Spontaneous closure of the fistula cannot be expected to occur, since the passage of food and saliva tends to keep the fistulous tract inflamed and patent. Because of a better prognosis, most of the interest in the management of these fistulas has been focused upon those secondary to infection or trauma.<sup>2</sup>Bronchoesophageal fistula resulting from carcinoma is usually a terminal manifestation and not amenable to curative therapy.1 Hodgkin's disease is a rare cause of bronchoesophageal fistula; however, the general improvement in the therapy for this disease may warrant a more aggressive therapeutic approach than that generally recognized. The present case report outlines a therapeutic approach which was used in the management of a patient with